Last reviewed 2026-04-20 · How we verify

Aspart

Aspart, developed by Emory University, is a marketed drug primarily indicated for improving glycemic control. The key composition patent for Aspart is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk for Aspart is the loss of exclusivity post-2028, which could significantly impact its market position.

At a glance

Approved indications

• Improving glycemic control

Common side effects

No common side effects on file.

Drug interactions

• antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics
• atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones
• alcohol, beta-blockers, clonidine, lithium salts, and pentamidine
• beta-blockers, clonidine, guanethidine, and reserpine

Key clinical trials

• Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
• Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D (NA)
• Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
• Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor
• Two Way Crossover Closed Loop MPC vs Control IQ (NA)
• Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers (PHASE2, PHASE3)
• Oral Anti Diabetic Agents in the Hospital (PHASE4)
• Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.